Novo Nordisk (CPSE:NOVO B) Extends GLP 1 Momentum, Is The Discount Now Too Wide?

Novo Nordisk (CPSE:NOVO B) has been busy on the clinical front, with fresh data on semaglutide and CagriSema, as well as regulatory updates on haemophilia candidate denecimig, now feeding into how investors reassess the stock.

Even with the latest semaglutide and CagriSema headlines, Novo Nordisk’s share price has been under pressure, with the 30-day share price return down 15.07% and the year-to-date share price return down 23.12%, while the 1-year total shareholder return has declined 30.80%. This signals fading momentum despite ongoing product news.

Pressure on Novo Nordisk shares can open opportunities elsewhere in the same space, so scan a curated group of under-pressure quality plays with the 184 high quality undervalued stocks.

Novo Nordisk now trades at a steep intrinsic discount and a double digit gap to analyst targets after a sharp reset in sentiment. Is that simply mispricing, or is the market correctly pricing in more caution around this story?

Most Popular Narrative: 70% Undervalued

Novo Nordisk last closed at DKK253.90, while the most followed narrative pegs fair value at about DKK851, which frames today’s share price reset very differently to the recent chart.

With high barriers to entry, a booming market for obesity treatment, and a pipeline that keeps expanding, Novo Nordisk’s future looks remarkably secure. The company also benefits from deep expertise, a strong brand, and a massive manufacturing network that rivals would struggle to replicate.

See why 91 investors see Novo Nordisk as 70% undervalued.

Result: Fair Value of DKK851 (UNDERVALUED)

Still, this narrative could be challenged by tougher pricing pressure on GLP-1 drugs and any setback in Novo Nordisk's obesity or rare disease pipeline.

Find out about the key risks to this Novo Nordisk narrative.

Next Steps

Sentiment on Novo Nordisk is clearly split, so consider reviewing the underlying numbers promptly and form your own stance using the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Novo Nordisk?

If Novo Nordisk has sharpened your focus on pricing, risk and opportunity, use these targeted screeners to surface other candidates before the crowd catches on.

• Hunt for mispriced quality by scanning the 184 high quality undervalued stocks that currently trade below their assessed worth with strong fundamentals to back the thesis.
• Prioritise staying power by filtering for companies on the list of solid balance sheet and fundamentals (207 results) that pair healthier finances with more resilient business models.
• Get ahead of the next wave by reviewing the 619 high quality undiscovered gems that combine sturdy financials with lower market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com